Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026)
Johnson & Johnson (JNJ) posted Other Working Capital Changes of -$349.0 million for Q1 2026, up 76.51% sequentially from -$1.5 billion in Q4 2025, and down 126.5% YoY from $1.3 billion in Q1 2025.
Johnson & Johnson (JNJ) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Other Working Capital Changes data on file, last reported at -$349.0 million in Q1 2026.
- Quarterly Other Working Capital Changes fell 126.5% year-over-year to -$349.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 billion (up 60.81% YoY) and the FY2025 annual result came in at $6.2 billion, up 459.17% from the prior year.
- Other Working Capital Changes improved to -$349.0 million in Q1 2026 per JNJ's latest filing, from -$1.5 billion in the prior quarter.
- The five-year high for Other Working Capital Changes was $4.9 billion in Q2 2025, with the low at -$3.2 billion in Q1 2024.
- Average Other Working Capital Changes over 5 years is $532.1 million, with a median of $229.0 million recorded in 2023.
- The widest YoY moves for Other Working Capital Changes: up 1153.15% in 2024, down 449.62% in 2024.
- Johnson & Johnson's Other Working Capital Changes stood at -$995.0 million in 2022, then soared by 312.46% to $2.1 billion in 2023, then sank by 136.33% to -$768.0 million in 2024, then plunged by 93.49% to -$1.5 billion in 2025, then surged by 76.51% to -$349.0 million in 2026.
- Business Quant data shows JNJ's Other Working Capital Changes at -$349.0 million in Q1 2026, -$1.5 billion in Q4 2025, and $1.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -349.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Mar 29, 2026 | -349.00 Mn |
| Dec 28, 2025 | -1.49 Bn |
| Dec 28, 2025 | -1.49 Bn |
| Dec 28, 2025 | -1.49 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Sep 28, 2025 | 1.46 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Jun 29, 2025 | 4.88 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Mar 30, 2025 | 1.32 Bn |
| Dec 29, 2024 | -768.00 Mn |
| Dec 29, 2024 | -768.00 Mn |
| Dec 29, 2024 | -768.00 Mn |
| Sep 29, 2024 | 2.78 Bn |
| Sep 29, 2024 | 2.78 Bn |